Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sevelamer Carbonate,Inapplicable
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 22, 2016
Lead Product(s) : Sevelamer Carbonate,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sevelamer Carbonate,Inapplicable
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2015
Lead Product(s) : Sevelamer Carbonate,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sevelamer Carbonate,Inapplicable
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2012
Lead Product(s) : Sevelamer Carbonate,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sevelamer Carbonate,Inapplicable
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2012
Lead Product(s) : Sevelamer Carbonate,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sevelamer Carbonate,Inapplicable
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives Approval from U.S. FDA for Sevelamer Carbonate for Oral Suspension
Details : Lupin received approval from the USFDA for its Abbreviated New Drug Application Sevelamer Carbonate for Oral Suspension, which is a generic equivalent of Renvela® for Oral Suspension, 0.8 g and 2.4 g Packets of Genzyme, used to treat increased phosphate...
Product Name : Sevelamer Carbonate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 25, 2021
Lead Product(s) : Sevelamer Carbonate,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sevelamer Carbonate,Inapplicable
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives Approval for Sevelamer Carbonate Tablets
Details : Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.
Product Name : Sevelamer Carbonate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 25, 2021
Lead Product(s) : Sevelamer Carbonate,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vadadustat,Sevelamer Carbonate,Calcium Acetate,Ferric Citrate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 09, 2020
Lead Product(s) : Vadadustat,Sevelamer Carbonate,Calcium Acetate,Ferric Citrate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenapanor,Sevelamer Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2019
Lead Product(s) : Tenapanor,Sevelamer Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenapanor,Sevelamer Carbonate,Ferric Citrate,Calcium Carbonate,Calcium Acetate,Iron Sucrose
Therapeutic Area : Nephrology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2019
Lead Product(s) : Tenapanor,Sevelamer Carbonate,Ferric Citrate,Calcium Carbonate,Calcium Acetate,Iron Sucrose
Therapeutic Area : Nephrology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paricalcitol,Cinacalcet Hydrochloride,Sevelamer Carbonate,Calcium Acetate,Magnesium Carbonate,Lanthanum Carbonate
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Optimal Anemia Treatment in End Stage Renal Disease (ERSD)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2014
Lead Product(s) : Paricalcitol,Cinacalcet Hydrochloride,Sevelamer Carbonate,Calcium Acetate,Magnesium Carbonate,Lanthanum Carbonate
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable